At the end of the Teva
7 February 2017

The Israeli pharmaceuticals company has lost its second chief executive in four years. Its next CEO faces tough times in America, where drugmakers’ pricing is under attack. Homegrown problems include bad acquisitions, tricky governance and an over-reliance on one drug.